Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, HERON THERAPEUTICS, INC. /DE/ reported revenue of $155M, up 7.4% year over year. Operating margin was -1.6% and net margin -13.0%, on a free-cash-flow margin of -18.0% with capital expenditure at 0.2% of revenue. Every figure is computed directly from HRTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $155M | -1.6% | -13.0% |
| FY2024 | $144M | -8.0% | -9.4% |
| FY2023 | $127M | -87.1% | -87.0% |
| FY2022 | $108M | -162.2% | -169.1% |
| FY2021 | $86M | -252.3% | -255.6% |
How does HRTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.